Join +750K new investors every month who copy stock picks from billionaire's portfoliosSign Up Free

Nasdaq And Eurozone: 2 ETFs To Watch On Outsized Volume

Published 10/06/2016, 10:52 PM
Updated 07/09/2023, 06:31 AM
SPY
-
SPY
-
DIA
-

Major U.S. benchmarks ended mostly flat on Thursday following easing concerns about the European Central Bank’s (ECB) bond purchasing volume cut. Investors also remained cautious ahead of today’s non-farm payroll data. Meanwhile, a decline in biotech stocks had a negative impact on the Nasdaq. Among the top ETFs, investors saw (AX:SPY) gain nearly 0.1%, while (V:DIA) decreased nearly 0.1% and QQQ fell about 0.1% on the day.

Two more specialized ETFs are worth noting in particular though as both saw trading volume that was far outside of normal. In fact, in the most recent trading session, both these funds experienced volume levels that were more than double their average. This could make these ETFs the ones to watch out for in the days ahead to see if this trend of extra interest continues:

FEUZ: Volume 4.83 times average

This Eurozone ETF tracking the NASDAQ AlphaDEX Eurozone Index was in focus yesterday as roughly 3,000 shares moved hands compared with an average of roughly 660 shares. FEUZ gained over 0.3% on the day.

Victor Constancio, Vice President of ECB declined rumours that the volume of quantitative easing program will get reduced. He also said that the bank will continue with its bond purchasing program until it achieves its inflation rate target. These had a positive impact on the ETF. However, in the last one-month period, FEUZ was down about 1%.

ONEQ: Volume 3.16 times average

This Nasdaq ETF was under the microscope on Thursday as nearly 61,700 shares moved hands. This compares to an average trading volume of 18,880 shares and came as ONEQ lost about 0.3% in the session.

A decline in biotech stocks led the Nasdaq to end in the negative territory yesterday, which in turn dragged this Nasdaq tracking ETF down. iShares Nasdaq Biotechnology IBB declined 2.3% on the day following a 48.4% plunge in Alnylam Pharmaceuticals’ shares, which announced the termination of testing of its drug, revusiran. However, in the last one-month period, ONEQ was up nearly 0.2%.

Want key ETF info delivered straight to your inbox?

Zacks’ free Fund Newsletter will brief you on top news and analysis, as well as top-performing ETFs, each week. Get it free >>



SPDR-DJ IND AVG (DIA): ETF Research Reports

SPDR-SP 500 TR (SPY (NYSE:SPY)): ETF Research Reports

ISHARES NDQ BIO (IBB): ETF Research Reports

NASDAQ-100 SHRS (QQQ): ETF Research Reports

FT-EUROZN ALPHD (FEUZ): ETF Research Reports

FIDLTY NDQ CMP (ONEQ): ETF Research Reports

Original post

Zacks Investment Research

Latest comments

Loading next article…
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.